Cohance Lifesciences Ltd
₹311.95
(3.48%)
Sat, 04 Apr 2026, 08:00 am
Health Technology
Pharmaceuticals: Major
24.5KCohance Lifesciences Price to Cash Flow Ratio
| Particulars | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 16.18 | 34.80 | 34.66 | 29.26 | 57.36 | 110.76 |
| Price to book ratio | 0 | 3.04 | 10.68 | 10.30 | 6.93 | 8.40 | 17.40 |
| Price to sales ratio | 0 | 6.27 | 12.67 | 12.04 | 9.04 | 16.63 | 25.14 |
| Price to cash flow ratio | 0 | 13.18 | 33.73 | 48.58 | 26.66 | 45.21 | 104.19 |
| Enterprise value | 0 | 52.7B | 125.64B | 152.99B | 116.17B | 164.64B | 298.04B |
| Enterprise value to EBITDA ratio | 0 | 14.14 | 28.48 | 26.19 | 19.90 | 40.67 | 74.62 |
| Debt to equity ratio | 0.14 | 0.22 | 0.12 | 0.06 | 0.04 | 0.03 | 0.16 |
| Return on equity % | 0 | 44.18 | 35.78 | 33.52 | 25.21 | 15.86 | 14.30 |
Cohance Lifesciences Ltd Price to Cash Flow Ratio
The Cohance Lifesciences Ltd Price to Cash Flow Ratio is a key financial metric used by investors to evaluate Cohance Lifesciences Ltd's valuation, profitability, and overall financial performance. Tracking the Cohance Lifesciences Ltd Price to Cash Flow Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Cohance Lifesciences Ltd (NSE: COHANCE, BSE: 543064) is currently trading at ₹311.95, with a market capitalization of ₹115.5B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Cohance Lifesciences Ltd Price to Cash Flow Ratio is essential for fundamental analysis.
Cohance Lifesciences Ltd Price to Cash Flow Ratio Current Value
The current Cohance Lifesciences Ltd Price to Cash Flow Ratio stands at 104.19.
The latest Cohance Lifesciences Ltd Price to Cash Flow Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Cohance Lifesciences Ltd Price to Cash Flow Ratio Historical Trend
The Cohance Lifesciences Ltd Price to Cash Flow Ratio has shown the following historical trend:
- 2024: 104.19
- 2023: 45.21
- 2022: 26.66
- 2021: 48.58
- 2020: 33.73
The recent rise in Cohance Lifesciences Ltd Price to Cash Flow Ratio suggests strengthening valuation trends and improving market sentiment.
What Cohance Lifesciences Ltd Price to Cash Flow Ratio Indicates for Investors
The Cohance Lifesciences Ltd Price to Cash Flow Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/CF ratio indicates how much investors pay for company cash flow.
Cohance Lifesciences Ltd Price to Cash Flow Ratio Analysis Summary
The Cohance Lifesciences Ltd Price to Cash Flow Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Cohance Lifesciences Ltd Price to Cash Flow Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Cohance Lifesciences Ltd Price to Cash Flow Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800